Literature DB >> 30094524

Using Clinical PK/PD Studies to Support No Clinically Meaningful Differences Between a Proposed Biosimilar and the Reference Product.

Peijuan Zhu1, Ping Ji2, Yaning Wang2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30094524     DOI： 10.1208/s12248-018-0246-1

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


× No keyword cloud information.
  10 in total

Review 1.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

Review 2.  Biomarkers and surrogate markers: an FDA perspective.

Authors:  Russell Katz
Journal:  NeuroRx       Date:  2004-04

3.  The state of the art in the development of biosimilars.

Authors:  Mark McCamish; Gillian Woollett
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

4.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

Authors:  Martin Schiestl; Thomas Stangler; Claudia Torella; Tadej Cepeljnik; Hansjörg Toll; Roger Grau
Journal:  Nat Biotechnol       Date:  2011-04       Impact factor: 54.908

5.  Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.

Authors:  Peijuan Zhu; Sherwin K B Sy; Andrej Skerjanec
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

Review 6.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

7.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

8.  Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hisashi Yamanaka; Yoshiya Tanaka; Takeo Sakurai; Kazuyoshi Saito; Hideo Ohtsubo; Sang Joon Lee; Yoshihiro Nambu
Journal:  Mod Rheumatol       Date:  2015-04-02       Impact factor: 3.023

9.  A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.

Authors:  Josef S Smolen; Stanley B Cohen; Hans-Peter Tony; Morton Scheinberg; Alan Kivitz; Andra Balanescu; Juan Gomez-Reino; Liyi Cen; Peijuan Zhu; Tamas Shisha
Journal:  Ann Rheum Dis       Date:  2017-06-21       Impact factor: 19.103

10.  Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.

Authors:  Elizabeth Hyland; Tim Mant; Pantelis Vlachos; Neil Attkins; Martin Ullmann; Sanjeev Roy; Volker Wagner
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335
  10 in total
  1 in total

1.  Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.

Authors:  Justin Stebbing; Paul N Mainwaring; Giuseppe Curigliano; Mark Pegram; Mark Latymer; Angel H Bair; Hope S Rugo
Journal:  J Clin Oncol       Date:  2020-02-14       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.